Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat

Antisense and Nucleic Acid Drug Development

Volumn 11, Issue 1, 2001, Pages 15-27

  Peng, B ^a,b   Andrews, J ^a   Nestorov, I ^a   Brennan, B ^a   Nicklin, P ^c   Rowland, M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISIS 1082; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; IN VIVO STUDY; KIDNEY PARENCHYMA; LIVER; MALE; MODEL; MUSCLE TISSUE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 0035094632     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729001750072092     Document Type: Article

References (27)

1. Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice
2. Pharmacokinetics of antisense oligonucleotides
3. Comparative pharmacokinetics of fentanyl and alfentanil in rats and humans based on parametric single-tissue models
4. Quantitative structure pharmacokinetics relationships. I. Development of a whole body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in rat
5. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats
6. Therapeutic applications of oligonucleotides
7. Pharmacokinetic properties of several novel oligonucleotide analogs in mice
8. Physiological parameters in laboratory animals and humans
9. Reduction of herpes simplex virus infection using phosphorothioate oligonucleotides complementary to viral mRNA
10. From piecewise to full pharmacokinetic modeling: Application to thiopental disposition in the rat
11. Antisense oligonucleotide inhibitors for the treatment of cancer: I. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides
12. In vivo distribution and metabolism of a phosphorothiate oligonucleotide within rat liver after intravenous administration
13. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1
14. Physiologically based pharmacokinetic study on a cyclosporine derivative, SDZ IMM 125
15. Physiologically based pharmacokinetics of cyclosporin A: Extension to tissue distribution kinetics in rats and scale-up to human
16. Quantitation of phosphorothioate oligonucleotides in human plasma
17. In vitro and in vivo pharmacologic activities of antisense oligonucleotides
18. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): Comparison with other delivery routes
19. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration
20. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice
21. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate
22. Physiologically based pharmacokinetics of radioiodonated human beta-endorphin in rats. An application of the capillary membrane-limited model
23. Co-administration of polyanions with a phosphorothioate oligonucleotide (CGP 69846A): A role for the scavenger receptor in its in vivo disposition
24. Antisense oligonucleotides. A new therapeutic principle
25. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (gem 91) developed as a therapeutic agent for human immunodeficiency virus type-1